Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Calliditas Therapeutics Suisse SA
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05014672CT.gov A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness | — | Completed | — | — | — |
NCT03226067CT.gov Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Biliary Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Setanaxib (this asset) | Calliditas Therapeutics Suisse SA | P2 | B · 62 |
| Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | P4 | A |
| Saroglitazar | Zydus Therapeutics Inc. | P3 | BB |
| Fenofibrate | Xijing Hospital of Digestive Diseases | P3 | BB |
| Seladelpar | Gilead Sciences | P3 | BB |
| cs0159 | Cascade Pharmaceuticals, Inc | P3 | BB |
| Obeticholic Acid | Intercept Pharmaceuticals | P3 | BB |
| 2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID | Intercept Pharmaceuticals | P3 | BB |
| Rituximab | Newcastle-upon-Tyne Hospitals NHS Trust | P2 | BB |
+41 more in the Primary Biliary Cholangitis cohort
Other indications for Setanaxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fibrotic Liver Disease | — | P2 | B · 57 |
| Idiopathic Pulmonary Fibrosis | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Setanaxib in Primary Biliary Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/setanaxib-primary-biliary-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →